Game Changer? DTx on Drug Labels

The digital therapeutics market has experienced fluctuations, but a potential turning point has emerged with the release of new FDA guidance. This regulatory direction, released in September 2023, outlines a pathway for incorporating DTx into drug labels, signalling a significant development for the industry.

Essentially, DTx on drug labels signifies a synergy between traditional medicine and digital interventions. This fusion enhances treatment strategies, addressing medication adherence and fostering continuous patient engagement. This represents a game-changing evolution, allowing healthcare providers to offer more holistic and effective approaches, marking a new frontier in medicine.

Join your peers to explore the impact of integrating DTxs on drug labels and its potential to enhance patient adherence and healthcare delivery. More specifically, you’ll delve into:

• How does DTx on drug labels influence engagement with and adoption of medical software?
• What potential opportunities could emerge due to this game changing integration of DTx into drug labels?
• How does combining physical pharmaceuticals with DTx contribute to a more personalised healthcare approach?
• Will this cause Pharma to focus on DTx again?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.